Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Rituximab 134Cyclophosphamide 126Peripheral Blood Stem Cell Transplantation 74fludarabine phosphate 71Filgrastim 62Etoposide 56Bortezomib 44Vincristine 43Mycophenolic Acid 43Whole-Body Irradiation 42Cytarabine 42Cyclosporine 41Melphalan 38Doxorubicin 37Radiotherapy 36Busulfan 35ibrutinib 34Tacrolimus 34Methotrexate 33Prednisone 32Lenalidomide 30Bendamustine Hydrochloride 30Antilymphocyte Serum 27Dexamethasone 26Carmustine 26Granulocyte Colony-Stimulating Factor 23ibritumomab tiuxetan 20sargramostim 17fludarabine 17Methylprednisolone 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Mantle-Cell × merestinib × Clear all
NCT02745769 2019-03-05

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Eli Lilly and Company

Phase 1 Completed
23 enrolled
GastrointestinalLymphoid

Colorectal Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡